Forest plot of (A) median CD4 count and (B) median gains in CD4 count among HIV-infected FSWs on ART and starting ART.

<p>Study estimates are grouped by country income and ordered by time on ART. ^a N refers to a subset of FSWs who were eligible for ART upon HIV diagnosis and enrolled in HIV care following HIV diagnosis. ART  =  antiretroviral, FSW  =  female sex workers, CI  =  confidence interval, NR  =  not reported, N =  sample size of FSWs available for each outcome, N_p =  number of independent study populations, m =  median, IQR  =  interquartile range.</p

DCE physical attributes and levels.

<p>MCD: microbicide; DGM: Diaphragm; FC: Female condom; *Depending on what they did the last time they had sex, a card was placed over the attributes with the appropriate attribute levels for either using a male condom with its attributes, or no protection.</p

Predicted uptake of microbicides among women who had and had not used a condom.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0083193#pone-0083193-g003" target="_blank">Figure 3</a> shows the probability of switching to a microbicide with different levels of HIV prevention effectiveness, pregnancy prevention effectiveness and price, according to whether she had used a condom or not in her last sex-act and predicted population level uptake. The choice is between the microbicide and a free female condom (with 95% protection against HIV and pregnancy), or neither. The light bars on the left are the probabilities for women who reported having used a condom in their last sex-act, on the darker bars on the right are the probabilities for women who had not used a condom in their last sex-act, the vertical line shows the predicted population level. The base case is modelled close to the CAPRISA 004 trial effectiveness results (54% effective against HIV and no pregnancy effectiveness). On the very left, it can be seen that an expensive microbicide with low prevention effectiveness would have a low probability of being chosen. As the product characteristics improve (towards the right of the figure), women find the product becomes more and more attractive relative to the female condom or what they did last time.</p

Forest plot of viral suppression among HIV-infected FSWs on ART.

<p>Study estimates are grouped by country income and ordered by time on ART. The star symbol (*) highlights the study estimates (one per study population) included in the pooled overall estimate. For studies providing estimates over multiple time-periods, only one estimate was used for pooling (the most recent estimate from that study). I² and p-values are the measures of heterogeneity used. ART  =  antiretroviral, FSW  =  female sex workers, CI  =  confidence interval, NR  =  not reported, n =  number of FSWs with each outcome, N =  sample size of FSWs available for each outcome, N_p =  number of independent study populations, m =  median.</p

Overview of coverage assumptions in modelling impact and cost-effectiveness oral prep, microbicides and vaccines (2010

<p>–<b>2013).</b> The middle box represents the main estimate, with the vertical lines showing ranges included.</p

Flow diagram of search strategy and study selection process.

<p>FSW  =  female sex worker, ART  =  antiretroviral therapy, N_s =  number of studies.</p

Forest plot of current ART use among HIV-infected FSWs.

<p>Study estimates are grouped by country income and ordered by study-period. The star symbol (*) highlights the study estimates (one per study population) included in the pooled overall or subgroup estimates. Only study estimates with a known time period of data collection which were measured among at least 10 FSWs were used for pooling. I² and p-values are the measures of heterogeneity used. ^a ART was provided to FSWs in the Kenyan cohort from 2004, ^b Sample is ‘active’ FSWs, ^c Sample is ‘active’ and ‘former’ FSWs. ART  =  antiretroviral therapy, FSW  =  female sex workers, CI  =  confidence interval, NR  =  not reported, n =  number of FSWs with each outcome, N =  sample size of FSWs available for each outcome, N_p =  number of independent study populations.</p

Relative preferences for products and their characteristics.

<p>Note: All full product preferences are based on free distribution. Best profiles are specified as microbicides and the diaphragm able to be used in secret and with 95% protection against pregnancy and HIV for all products. Worst profiles are specified as not being able to be used in secret and the lowest product specific effectiveness included in the experiment (i.e. prevention effectiveness: 75% for the diaphragm and female condom and 0% for microbicides; for HIV prevention effectiveness: 35% for the diaphragm and microbicide and 75% for the female condom).</p

An example of the choice task.

<p>An example of the choice task.</p

Forest plot of ever ART use among HIV-infected FSWs.

<p>Study estimates are grouped by country income and ordered by time-period. The star symbol (*) highlights the study estimates (one per study population) included in the pooled overall or subgroup estimates. I² and p-values are the measures of heterogeneity used. ^a Sample is ‘active’ FSWs, ^b Sample is ‘active’ and ‘former’ FSWs. ART  =  antiretroviral therapy, FSW  =  female sex workers, CI  =  confidence interval, n =  number of FSWs with each outcome, N =  sample size of FSWs available for each outcome, N_p =  number of independent study populations.</p